NFL Biosciences develops botanical drugs to treat addictions, focusing on tobacco, alcohol, and cannabis. Their pipeline includes innovative drug candidates like NFL-101 and NFL-102 for smoking cessation, and NFL-301 for excessive alcohol consumption, aiming to license these to pharmaceutical laboratories. The company leverages scientific expertise in botanical medicines and conducts preclinical and clinical studies.